This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Early Detection and Intervention for Mild and Moderate Lymphedema in Patients Treated for Breast Cancer

This study has been terminated.
(low accrual)
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Alphonse Taghian, MD, PhD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00959985
First received: August 14, 2009
Last updated: April 26, 2017
Last verified: April 2017
Results First Received: January 4, 2017  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Lymphedema
Breast Cancer
Interventions: Device: Compression Sleeve
Device: Short-Stretch Compression Bandage

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Group 1A Mild Lymphedema: Only required to meet with the lymphedema physical therapist
Group 1B

Mild Lymphedema: Fitted for compression sleeve

Compression Sleeve: Worn for a minimum of 12 hours per day

Group 2A

Moderate lymphedema: Fitted with a compression sleeve

Compression Sleeve: Worn for a minimum of 12 hours per day

Group 2B

Moderate Lymphedema: Fitted with compression sleeve and instructed to wear a short-stretch compression bandage

Compression Sleeve: Worn for a minimum of 12 hours per day

Short-Stretch Compression Bandage: Worn overnight at least 5 nights of the week


Participant Flow:   Overall Study
    Group 1A   Group 1B   Group 2A   Group 2B
STARTED   8   7   4   4 
COMPLETED   8   7   4   4 
NOT COMPLETED   0   0   0   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Group 1A Mild Lymphedema: Only required to meet with the lymphedema physical therapist
Group 1B

Mild Lymphedema: Fitted for compression sleeve

Compression Sleeve: Worn for a minimum of 12 hours per day

Group 2A

Moderate lymphedema: Fitted with a compression sleeve

Compression Sleeve: Worn for a minimum of 12 hours per day

Group 2B

Moderate Lymphedema: Fitted with compression sleeve and instructed to wear a short-stretch compression bandage

Compression Sleeve: Worn for a minimum of 12 hours per day

Short-Stretch Compression Bandage: Worn overnight at least 5 nights of the week

Total Total of all reporting groups

Baseline Measures
   Group 1A   Group 1B   Group 2A   Group 2B   Total 
Overall Participants Analyzed 
[Units: Participants]
 8   7   4   4   23 
Age 
[Units: Participants]
Count of Participants
         
<=18 years      0   0.0%      0   0.0%      0   0.0%      0   0.0%      0   0.0% 
Between 18 and 65 years      5  62.5%      5  71.4%      4 100.0%      3  75.0%      17  73.9% 
>=65 years      3  37.5%      2  28.6%      0   0.0%      1  25.0%      6  26.1% 
Sex: Female, Male 
[Units: Participants]
Count of Participants
         
Female      8 100.0%      7 100.0%      4 100.0%      4 100.0%      23 100.0% 
Male      0   0.0%      0   0.0%      0   0.0%      0   0.0%      0   0.0% 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   To Identify the Number of Patients Who Experienced Reduction in Edema With Compression Garment Usage for Low Volume Lymphedema Associated With Breast Cancer Treatment   [ Time Frame: 5 years ]

2.  Primary:   To Identify the Number of Patients Who Experienced Reduction in Edema With Compression Garments +/- Night Compression Bandaging for Moderate Volume Lymphedema Due to Breast Cancer Treatment   [ Time Frame: 5 years ]

3.  Primary:   To Assess Survey Response Scores Regarding Symptoms Associated With Varying Degrees of Lymphedema   [ Time Frame: 5 years ]

4.  Primary:   To Assess Survey Response Scores Regarding Fear Avoidance Behavior Associated With Varying Degrees of Lymphedema   [ Time Frame: 5 years ]

5.  Primary:   To Assess Survey Response Scores Regarding Quality of Life as it Associated With Varying Degrees of Lymphedema   [ Time Frame: 5 years ]

6.  Primary:   To Assess Survey Response Scores Regarding Upper Extremity Function as it Associated With Varying Degrees of Lymphedema   [ Time Frame: 5 years ]

7.  Secondary:   To Identify the Number of Patients With Risk Factors Associated With the Onset of Lymphedema That Are Both Related and Unrelated to Treatment for Breast Cancer   [ Time Frame: 5 years ]

8.  Secondary:   To Evaluate the Number of Patients With Low-level Arm Swelling in Order to Understand the Natural History of Lymphedema After Treatment for Breast Cancer   [ Time Frame: 5 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
This trial was terminated due to slow accrual and small number of subjects for whom data was collected (23 out of expected 334). Study did not reach statistical power to conduct detailed analysis, results should be interpreted with this in mind


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Alphonse G Taghian, MD PhD
Organization: Massachusetts General Hospital
phone: 617-726-6050 ext 24369
e-mail: ataghian@partners.org



Responsible Party: Alphonse Taghian, MD, PhD, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00959985     History of Changes
Other Study ID Numbers: 08-308
R01CA139118 ( U.S. NIH Grant/Contract )
Study First Received: August 14, 2009
Results First Received: January 4, 2017
Last Updated: April 26, 2017